Podcasts about Naim

Send us a textKey Opinion Leaders Manal Abdelmalek, Naim Alkhouri, Scott Isaacs and Zobair Younossi join Roger Green to discuss the FDA's approval of semaglutide for patients with non-cirrhotic MASH. This conversation centers on the roles that new technologies and an expanded APP population will play in MASLD and MASH management in the US, and concludes by exploring how care might look different 12 months from now, and then in subsequent years. As panelists identify some of the changes they foresee if we are to manage the tsunami of undiagnosed MASLD patients, many comments touch on themes discussed earlier in this episode. A couple are unique. Zobair and Scott discuss the increased role that artificial intelligence and big data analytics will play in identifying high-risk patients and improving clinical pathways. Additionally, Zobair notes that we must remember that the vast majority of MASLD patients will never develop MASH. Manal foresees a more sophisticated approach to selecting pharmacotherapies as prescribers have a broader set of options, each with its own benefits and drawbacks. Scott anticipates a "paradigm shift" in which endocrinologists view MASH similarly to how they view retinopathy, neuropathy and retinopathy. Naim suggests that one year will not look tremendously different from today, but that five years from now will be an entirely different picture, which he describes in some detail. 

Send us a textKey Opinion Leaders Manal Abdelmalek, Naim Alkhouri, Scott Isaacs and Zobair Younossi join Roger Green to discuss  FDA's approval of semaglutide for patients with non-cirrhotic MASH. This conversation focuses on benefits for patients and ways that having two drugs with different modes of action will change pharmacotherapy choices.This conversation starts with the group describing the sense of "enthusiasm" and "fulfillment" hepatology drug developers feel to see two drugs approved in the US and many other major changes to come (more drug approvals, FDA acceptance of a path to approval that is not based on liver biopsy). One interesting takeaway is that while the approval of semaglutide will likely change the number of patients treated with MASH pharmacotherapy, the greater impact of this approval will be on public awareness of MASH and the accompanying demand for treatment. In terms of actual drug use, the first major change will come among patients living with obesity but not Type 2 diabetes. Most of these patients previously saw their semaglutide prescriptions rejected for payment by health insurers. However, many of these patients will be living with MASH, and they are likely to see their prescriptions approved. Instead, the largest impact may involve increased education and awareness. Scott pointed out that endocrinologists, who frequently prescribe incretin agonists, will have reason to learn how to diagnose and manage MASH in patients they already treat. Zobair noted that an array of companies, starting with pharmaceutical manufacturers and scanning companies, will dramatically increase investments in prescriber and patient education. Another important benefit may come in terms of coverage. Scott points out that most patients living with obesity but not diabetes are unlikely to have their semaglutide prescriptions covered by commercial insurers. Those living with non-cirrhotic MASH are likely to have semaglutide covered. A separate but related point: Naim reports that ~30% of the MASH patients he sees are taking an incretin agonist at the time of initial visit.

Send us a textKey Opinion Leaders Manal Abdelmalek, Naim Alkhouri, Scott Isaacs and Zobair Younossi join Roger Green to discuss the FDA's approval of semaglutide for patients with non-cirrhotic MASH. This conversation focuses on how the US healthcare system must adapt to handle the growing number of MASH and MASLD patients who might seek treatment, given likely increases in publicity and education.The conversation starts with a focus on the implications of semaglutide approval for hepatologists. Naim states that many hepatologists are currently uncomfortable managing patients on GLP-1 agonists. This will need to change. Manal points out that providers must check for cirrhosis when testing for MASH and understand how to respond accordingly. An increase in the number of providers having access to in-office scanning devices will facilitate this process.Zobair shifts to a larger point:  even if all related specialists integrate MASH into their practices, the actual patient care demand will require alternative pathways in which the responsibility for patient care will rest with specialist APPs. The number of APPs necessary to handle this load and trained to do so does not currently exist in the US. Increased APP training must, and will, become an area for increased investment and focus.After Naim Alkhouri describes some of the differences between resmetirom and semaglutide in terms of practical treatment decisions, the discussion focuses on why MASLD and MASH will create unique challenges for hepatology practices. Manal views the issue as a matter of time; practices cannot absorb large numbers of new, non-urgent patients. Naim suggests that the real issue is the business question: specialists today do not profit simply from treating patients. Zobair agrees with Naim and notes that the challenge is not unique to hepatology. He expresses the hope that AI and efficient database management will make it easier to target, screen, diagnose and treat patients...given sufficient providers (mostly APPs) to treat them. 

Send us a text00:00:00 - Surf's Up, Season 6, Episode 12This week's episode is a special three-part roundtable on the implications of the FDA's recent approval of semaglutide. Naim Alkhouri, Manal Abdelmalek, Scott Isaacs and Zobair Younossi join Roger Green in a discussion that focuses less on specifics of pharmacotherapy and more on how having two drugs available will change MASH management in the US.00:08:45 - Part I: How Will The Semaglutide Approval Affect Patient Treatment and Pharmacotherapy?The group starts by describing the sense of "enthusiasm" and "fulfillment" hepatology drug developers feel to see two drugs approved in the US and many other major changes to come (more drug approvals, FDA acceptance of a path to approval that is not based on liver biopsy). One interesting takeaway is that while the approval of semaglutide will likely change the number of patients treated with MASH pharmacotherapy, the greater impact of this approval will be on public awareness of MASH and the accompanying demand for treatment. In terms of actual drug use, the first major change will come among patients living with obesity but not Type 2 diabetes. Most of these patients previously saw their semaglutide prescriptions rejected for payment by health insurers. However, many of these patients will be living with MASH, and they are likely to see their prescriptions approved. Instead, the largest impact may involve increased education and awareness. Scott pointed out that endocrinologists, who frequently prescribe incretin agonists, will have reason to learn how to diagnose and manage MASH in patients they already treat. Zobair noted that an array of companies, starting with pharmaceutical manufacturers and scanning companies, will dramatically increase investments in prescriber and patient education.00:25:30 - Part II: How the Structure of Medical Practice Is Likely To ChangeNaim states that many hepatologists are currently uncomfortable managing patients on GLP-1 agonists. This will need to change. Manal points out that providers must check for cirrhosis when testing for MASH and understand how to respond accordingly. An increase in the number of providers having access to in-office scanning devices will facilitate this process. Zobair states that even if all related specialists integrate MASH into their practices, the actual patient care demand will require alternative pathways in which the responsibility for patient care will rest with specialist APPs. After Naim Alkhouri describes some of the differences between resmetirom and semaglutide in terms of practical treatment decisions, the discussion focuses on why MASLD and MASH will create unique challenges for hepatology practices. Manal views the issue as a matter of time; practices cannot absorb large numbers of new, non-urgent patients. Naim suggests that the real issue is the business question: specialists today do not profit simply from treating patients. Zobair agrees with Naim and notes that the challenge is not unique to hepatology. He expresses the hope that AI and efficient database management will make it easier to target patients, screen, diagnose and treat them. 00:44:17 - Part III: What Happens Next?In this final section, panelists identify some of the changes they foresee if we are to manage the tsunami of undiagnosed MASLD patients. Many of the comments touch on themes discussed earlier in this episode, but a couple are unique. Zobair states we must remember that the vast majority of MASLD patients will never develop MASH. Manal foresees a more sophisticated approach to selecting pharmacotherapies as prescribers have a broader set of options, each with its own benefits and drawbacks. Scotts anticipates a "paradigm shift" in which providers come to view MASH similarly to how they view diabetic comorbidities. 

HEADLINES:• GCC Nations Dominate Arab Salary Rankings!• AI Is Now Helping Dubai Beat Traffic Jams!• An Emirati Man's Construction Site Apology Is Winning Praise• A Resident Shares Her Opinion About People Filming Their Good Deeds• Should Interns Be Paid? Career Ladder Secrets From Recruitment Expert

Send us a textHepatologist and hepatology key opinion leader Naim Alkhouri joins Roger Green to remember his longstanding relationship with Stephen Harrison, announce his new role as Chief Academic Officer at Summit Clinical Research and share how, in this role, he will have exciting new avenues make an impact on many elements of MASH drug development and patient care. The conversation can be divided into two sections. In the first, Naim recounts his relationship with Stephen Harrison, beginning with his move to a different San Antonio clinical trial practice and continuing through his tenure at Arizona Liver Health, up until Stephen's untimely passing last April. He describes what it was like to work with Stephen, the man, and to learn from and share ideas with Stephen, the "visionary." Next, Naim announces that he has joined Summit Clinical Research as Chief Academic Officer. He describes the many aspects of his new role, from collaborating with Gail Hinkson, Mazen Noureddin and the rest of the Summit team in designing better clinical trials to the many kinds of medical education Summit can bring to various medical stakeholders. He describes the dramatic growth in the number of trial sites in the Summit network and additional growth he foresees. Like Gail Hinkson in the same episode, he discusses ways in which Alzheimer's drug development is similar to MASH. He also touches on obesity trials and the ways that Summit can help create more robust knowledge about obesity, not only through trials but also expert advisory boards. In the end, he makes a personal announcement that you will have to read to learn.

Send us a text00:00:00 - Surf's Up: Episode 6.9This conversation covers three topics. The first discusses the challenges of behavior change in dietary habits and ways governments can help, the second looks at what one can learn from wearing a CGM for 30 days, and the third celebrates the late Stephen Harrison while looking into the future of clinical trials and medical education. 00:06:12 - Global Think-Tank on SLD Roundtable, Part 3Behavior consultant Dr. Kristina Curtis joins Jörn Schattenberg, Louise Campbell and Roger Green to discuss issues related to patient-centered care. This conversation starts by focusing on the unique challenges that come with changing dietary habits. Changing this behavior is so challenging because the issues are so complex. People lack education about healthy eating habits. Even when they do, the high-pressure world in which we live often makes it easier simply to offer children fast food. Even parents who know better might allow their children (or spouses, or selves) not to eat vegetables after a trying day. The panel proceeds to discuss steps politicians can take to encourage healthier living and lifestyles if they wish, and why some are easier to execute than others. Finally, the group shares why they felt "enlightened" when leaving the SLD, and perhaps a little less alone. 00:21:34 - Newsmaker: Fatty Liver Alliance President Mike BetelThis interview with Fatty Liver Alliance President Mike Betel focuses on Year 3 of his 30-day Glucose Challenge. Mike wears a continuous glucose monitor (CGM) for the entire month of July and provides daily videos on LinkedIn and the Fatty Liver Alliance website discussing what he learned. The first year was dedicated to teaching the impact of eating badly and the second year was similar, but less egregious. This year, Mike, who is pre-diabetic, set the goal of keeping his glucose in a "normal" range of 70-140 mg/dl. He did so successfully 97-98% of the time over the month, and discusses some of the tricks he learned that help keep glucose in range over that time (HINT: walking 10-15 minutes after meals helps a lot!). He also shares hints about how to look at overall weight (it's the fat that matters, not simple weight), why it is not healthy to believe you must finish every bite of food put in front of you, and how all this relates to sleep and overall health. He also provides seeds for thought about ways manufacturers and providers might educate patients effectively on these issues. 00:53:11 - Expert: Summit Clinical Research Chief Academic Officer Naim AlkhouriThis interview occurred in late April during our episode celebrating Stephen Harrison. Naim chose this interview to annouce that he was joining Summit as Chief Academic Officer. The first part of this discussion focuses on Stephen on two levels: the personal history between Naim and Stephen and the nature of the contributions Stephen has made to the science of MASH, and particularly clinical trial design. The second part of the interview discusses Naim's new role, the diffrent kinds of teaching, training and medical education he sees as pivotal to the future of MASLD and MASH therapies, and the other elements of his new role. While discuss the role, he shares several bright, challenging insights about when MASH-ville is heading. 01:15:09 - ConclusionThe business report discusses vacations on the SurfingMASH team, upcoming episodes, and grateful notes from Ukrainian listeners. 

Hussein Abdel Hussein, a distinguished research fellow at the Foundation for Defense of Democracies, joined us today to share his expertise on Middle Eastern politics, particularly focusing on the Druze community and regional dynamics. As a leading authority on the subject, Hussein brings extensive knowledge about the complexities of Syrian politics, inter-community relations, and the broader geopolitical landscape of the Middle East. His insights have been particularly valuable in understanding the current situation facing the Druze community, their defensive mindset, and the intricate relationships between various regional powers. Hussein’s deep understanding of Middle Eastern sovereignty challenges and his experience in analyzing regional conflicts makes him uniquely qualified to address the complex issues facing Syria and its minority communities. Druze Community and Israeli Intervention The meeting focused on the situation in Syria, particularly the Druze community and Israel’s intervention to protect them. Hussein Abdel Hussein, a research fellow at the Foundation for Defense of Democracies, explained the unique characteristics of the Druze, including their defensive mindset and loyalty to their host countries. He emphasized that the recent violence in Syria was not initiated by the Druze, who were instead defending themselves against invaders. The discussion highlighted the complexities of Middle Eastern politics and the challenges of prioritizing democratic elections and individual rights in a region with a different cultural and societal focus. Druze Plight and Shara’s Leadership Hussain discussed the situation in Syria, focusing on the Druze community’s plight and the actions of the new leader, Ahmad Shara, who previously had ties to Al-Qaeda. He criticized the approach of giving Islamists financial support, citing past failures, and emphasized the need for conditions to be set for Shara to gain trust. Hussain praised Israel’s intervention to protect the Druze and expressed frustration with Western countries, particularly the UK and France, for not supporting the Druze and for their previous role in backing Shara. He also highlighted the importance of shared power and concessions from Shara to ensure the safety of minority groups in Syria. Syria Post-Assad Governance Strategy Hussain and Shoshana discussed the situation in Syria, emphasizing the lack of a concrete plan for post-Assad governance. Hussain argued that the U.S. and its allies could support non-Islamist factions like the Druze, Kurds, and Christians without direct military involvement, focusing on diplomatic and economic support. They highlighted the roles of Turkey, Qatar, and Iran in supporting Sunni Islamists and the need to exclude these countries from any reconstruction plan. Hussain proposed aligning with allies like the UAE, Kuwait, Morocco, Israel, and Cyprus to create a stable, inclusive Syria under Assad’s presidency, with concessions made to him in exchange for cooperation. Druze Attacks: Turkish-Israeli Proxy War Hussain discussed the brutal attacks on the Druze in Syria, highlighting the involvement of two major clans from the northeast, Gaddat and Naim, which he believes were orchestrated by Syrian intelligence and Turkish interests, rather than being a simple tribal revenge. Shoshana raised questions about whether Al-Shara was directing these attacks and expressed skepticism about the possibility of a lasting peace if the attackers are true Islamists. Hussain explained that the main driver of the conflict in Syria is the competition between Turkey and Israel, and he suggested that the attack on the Druze was part of Turkey’s strategy to establish a foothold on the border with Israel. US-Turkey-Qatar Relations: Strategic Challenges Shoshana and Hussain discussed the complex dynamics between the US, Turkey, and Qatar, highlighting the challenges of balancing relations with Turkey as a NATO ally while addressing concerns about its and Qatar’s support for groups like Hamas. Hussain emphasized the need for an honest conversation with Turkey and Qatar, expressing frustration with their double-standard policies and calling for sanctions or confrontation if they continue undermining US interests. Shoshana raised questions about the US’s approach to negotiations with Hamas and Qatar, expressing skepticism about their willingness to align with US interests. Both participants expressed disappointment with the lack of action from Saudi Arabia and other Arab Gulf states in addressing regional issues, particularly in Syria and Lebanon, and questioned the effectiveness of current strategies in the region. Middle East Sovereignty Challenges Hussain and Shoshana discussed the challenges of self-determination and sovereignty in the Middle East, highlighting inconsistencies in how different groups are treated. They explored how nation-states have been imposed on various populations, with Hussain noting that the Gulf region’s success may be due to its organic evolution compared to forced European ideas in other areas. They agreed that the West cannot force these concepts on others but can offer guidance and suggestions. Hussain optimistically viewed Israel’s recent actions as creating a window of opportunity for positive change in the region. This recap was generate by computer. 

What a guest we have for you this week! Naim Cortazzi from Fun Lovin' Criminals, Uncle Frank, Radio Riddler and Fatal Star joins us to pick his ultimate dream band. Make sure you check him out here on InstagramEpisode 28 also brings you multiple tea chats!! Pick N Licks is presented by musicians Danny Beardsley and Dan Dan Hayes - The Dream Band Podcast, where guests create their ultimate dream band. Produced by Heather Beardsley. Hosted on Acast. See acast.com/privacy for more information.

00:00:00 - Surf's Up: Season 6 Episode 7Host Roger Green explains our recent vacation from publishing episodes, assures the audience that the podcast will continue weekly for months and years ahead, and discusses the episode's sections, covering the Global Think-Tank on Steatotic Liver Disease (SLD), the EASL patient screening activity and the increasing role of NITs in drug development. While introducing roundtable guests, he introduces first-time Surfer Dr. Kristina Curtis of the UK-based consultancy, Applied Behaviour Change.00:09:11 - Roundtable I: From the Global Think-Tank on SLDThis discussion starts with co-host Jörn Schattenberg discussing the history and evolution of the first four Global Think-Tanks as the focus shifts from educating medical professionals about liver disease to incorporating a broader group of stakeholders, including politicians and non-hepatologist MDs, to break down siloes and create wider awareness. Co-host Louise Campbell describes the breadth of stakeholders necessary to address this pandemic fully. She explains how her work with transient elastography and the MyLife365.me app constitutes a form of behavioral therapy. Jörn describes the test as a diagnostic and comments that the treatment is what health professionals do with the results. Kristina says that the behavioral change that results comes from well-delivered feedback. She describes "hybrid interventions, digital interventions with a human in the loop." Louise discusses results from the EASL late-breaker that support these findings and goes on to discuss the role AI can play in medical practices.00:23:50 - Newsmaker: Jose Willemse, Dutch Liver Patients Association This discussion covers two primary topics: (1) the Amsterdam screening activity that took place during EASL. Jose describes the phenomenal level of interest in this activity, in which hepatologists and APPs scanned 400 people per day for MASLD and MASH. Boosted by significant mass publicity in Amsterdam, the number of people seeking screening exceeded the 400/day quota, with some arriving in line hours before the scheduled start time and others traveling for hours to reach the site. Jose believes that with adequate publicity, efforts like these could be replicated around the world, but that the healthcare system lacks the necessary resources to do so. In terms of patient care, Jose emphasized the importance of sensitive yet frank conversations and helping patients appreciate the successes they are achieving. 00:53:45 - Roundtable II: NITs Increasing Role in Drug Development Sven Francque and Naim Alhouri joined Louise, Jörn and Roger for this roundtable, although Naim had dropped off by this time. The conversation starts with Louise noting that the goal of therapy is not simply to treat MASLD, but to achieve overall metabolic health, of which MASLD is a key component. Jörn states that we are on the path toward conducting clinical trials entirely with NITs as disease markers, which he describes as a "game changer" and Louise terms "exciting." She asks whether NITs can serve as the only trial surrogate. Jörn and Sven agree that we are not at that point yet, but we are headed in that direction. Jörn asserts that "nothing" will replace outcomes as the prerequisite for full approval and mentions the VCTE study group as demonstrating that a large NIT-based trial can prove effects on disease. Louise cautions that operator competency is a key, if overlooked, criterion for this kind of activity. Sven concurs and states that repeat measures are crucial in managing disease. Jörn notes that practices can serve as centers of care, but will need support from nutritionists and other professionals. 01:06:08 - Business ReportRoger highlights special September programming, indicates that new sponsors are on the way, and asks how many listeners find SurfingMASH on YouTube. 

En entrevista para MVS Noticias con Daniel Guerra, en ausencia de Ana Francisca Vega, Julio Serrano Espinosa, presidente del Centro de Estudios Espinosa Yglesias, habló sobre ¿Por qué se canceló el NAIM en Texcoco? El documental “Texcoco: la decisión del presidente” y lo que dejó una de las obras más polémicas de las últimas décadas. See omnystudio.com/listener for privacy information.

We explore New Testament chapter 23 from A Practical Commentary on Holy Scripture.Please support the Our Lady of Fatima Podcast:Buymeacoffee.com/TerenceMStantonLike and subscribe on YouTube:@OurLadyOfFatimaPodcastFollow us on X:@FatimaPodcastThank you!

Reapareció nuestro ex Peña Nieto y tiró factos sobre la suspensión del NAIM. AlertaAbelina, AlertaAbelina: Las plantas producen dióxido de carbono y con eso ayuda a la erosión. ¿Cómo le fue al Jr en su pelea y qué dijo su padre al respecto? Y puede haber final de DT's mexicanos en la CopaOro. Y a Christián Chávez le "motivaba" ver a HeMan.

Nous vous embarquons au cœur de l'effervescence matinale de l'aéroport du Havre-Octeville, où un vol à destination de la Slovénie s'apprête à décoller. Des coulisses techniques aux voix qui rythment les opérations aériennes, suivez les acteurs clés de cette mécanique bien huilée.Rencontre avec Pierrick et Pierre, agents de piste et pompiers de l'aéroport, garants de la sécurité au sol.Naim, en charge de l'escale, nous ouvre les portes du voyage côté logistique.Et direction la tour de contrôle avec Thomas, chef d'orchestre du trafic aérien.Derrière chaque vol, chaque valise, des métiers qu'on ne voit jamais : immersion dans les coulisses de vos vacances. 

På nyheterna: Putin, Gaza, Trump och plattmaskar. Men hur mår vi? Åtta svenskar, från norr till söder, släpper in oss i sina liv en vanlig dag i mars. Lyssna på alla avsnitt i Sveriges Radio Play. Edith går i sexan i Alingsås och oroar sig över sina betyg och ångrar att hon önskat sig sygrejer. I Västerås pluggar Naim till sjuksköterska och oroar sig för världskrig men är mest rädd för myror.I Aspudden har Fredrik sagt upp sig från sitt jobb för att känna sig fri och i Göteborg driver Nadja sin egen restaurang för att hon älskar att laga mat.I Piteå kämpar Sofia för sina barn och drömmer om Pompeji och i Vasastan drömmer Vlado om Sverige som det var förr, när människor lagade sina skor och Tage Erlander var statsminister.Men i Malmö känner Carl-Henrik framtidstro eftersom AI kommer göra världen bättre. Och i Vreten funderar Linn på om ett kafferep med Putin, hennes mormor och jobbarkompisarna från rörfirman skulle kunna rädda världsfreden.Dokumentären är gjord mars 2025.Reportrar: Anna FreyHåkan EngströmYlva LindgrenIda LundqvistLotta MalmstedtRandi Mossige-NorheimSofia KottorpProducenter: Anna FreyYlva LindgrenSlutmix: Sandra Pettersson

The word נעים means pleasant, or nice. Let's learn all about pleasantness – Guy teaches us sentences with this word that has had a long and successful career, along with Hebrew names related to its root. Oh, and how do you greet someone who just got a haircut in Arabic? Hear the All-Hebrew Episode on Patreon   New Words and Expressions: Naim – Pleasant, fine – נעים Mezeg avir naim – Nice weather – מזג אוויר נעים Naim meod – Nice meeting you – נעים מאוד Na'im lehakir – Nice meeting you – נעים להכיר Naim li me'od – Nice meeting you – נעים לי מאוד Ze lo na'im li – I don't like this (feeling) – זה לא נעים לי Slicha, mamash lo na'im li, aval… – Sorry, I feel awful saying this, but… – סליחה, ממש לא נעים לי, אבל Na'iman – An arabic blessing to a person who finished a shower or got a new haircut – נעימן – نعيماً “Ani holem al Naomi” – I dream about Naomi – אני חולם על נעמי Na'ama – Na'ama, a woman's first name – נעמה Noam – Pleasantness – נועם “Ata lo yachol la'asot et ze yoter be-noam?” – Can't you do it more pleasantly? – אתה לא יכול לעשות את זה יותר בנועם Be-noam – Pleasantly – בנועם Noam halichot – Peasant manners – נועם הליכות Ne'ima musikalit – Musical tune – נעימה מוסיקלית Biluy naim – Have a great time – בילוי נעים Tisa ne'ima – Have a pleasant flight – טיסה נעימה   Playlist and Clips: Ha-halonot Ha-gvohim – Kama Na'im (lyrics) Jana Mekdad – Naiman (Arabic) Yael Naim – New Soul Hedva & David – Ani Holem Al Neomi (lyrics) Hedva & David – Naomi No Yume (Japanese version) Yael Levy – Tmuna (lyrics) Ep. 58 about lo na'im li HEB

00:00:00 Surf's Up, Season 6, Episode 6.On April 23, 2024, our colleague and co-founder, Stephen Harrison, passed away suddenly. This week, Surfing the MASH Tsunami remembers Stephen with two of his closest associates and continues our annual MASH Drug Development roundtable held in his honor. 00:00:04:24 - A Deep Dive into Drug Development, Part 2The second portion of the Drug Development roundtable primarily focuses on three key issues. The first, uptake of resmetirom, starts with Naim Alkhouri discussing his experience in the Arizona Liver Health Clinics with over 650 patients in the year since resmetirom was approved and shifts to the various European panelists (Jörn Schattenberg, Louise Campbell and Sven Francque) estimating when it might be approved in their countries and how widely it might be reimbursed.  The second topic, incretin agonists, focuses on exciting prospects for other incretin agonists in development, as well as some semaglutide combination therapies. The third, NIT clinical trials, covers prospects that non-biopsy clinical trials might be approved sometime in the near future.00:16:20 - Remembering Stephen Harrison I: An Interview with Summit Clinical Research CEO Gail HinksonSummit CEO Gail Hinkson joins Roger Green for the first time on SurfingMASH to discuss her business partner. Gail discusses how the two originally formed Pinnacle Clinical Research and how Pinnacle led to Summit. She proceeds to discuss the current size and reach of both Pinnacle and Summit. Focusing on Summit, Gail describes the company as an Integrated Research Organization (IRO), highlighting its distinct role within the MASH firmament. In the final section of the interview, Gail discusses how Stephen's personality, goals, and vision continue to live on at Summit today.00:34:31 - Remembering Stephen Harrison II: An Interview with Naim Alkhouri Announcing That He Is Joining SummitNewly announced Summit Chief Academic Officer Naim Alkhouri joins this episode for a second time, but in a very different role. Naim discusses his personal history with Stephen and what he loved and respected about his "dear friend." He then makes a major announcement: he is joining Summit as Chief Academic Officer. He shares the many elements of this role, particularly his excitement that Summit can become the entity that educates a wide range of healthcare and commercial professionals on what MASH is and how it is treated. The scope of this vision, combined with what Gail discussed, portrays a level of energy, ambition and vision worthy of Stephen Harrison.00:55:55 - ConclusionAs part of this memorial week, Roger Green forgoes the usual business report, which will return next week.

Timna Naim is an MFA candidate in Spatial Arts whose work is playful, tactical, and socially engaging. They work primarily in clay and utilize performance, social practice, and experimental glazing techniques to make the fantastical tangible.Follow Timna's worktimnanaim.comInstagram: fireclaywater

This conversation is the opening segment of SurfingMASH's April discussion, in memory of Stephen A. Harrison, on drug development. In addition to co-hosts Jörn Schattenberg, Louise Campbell and Roger Green, panelists include hepatologists and key opinion leaders Sven Francque and Naim Alkhouri. This opening discussion focuses on exciting advances in one drug class (FGF-21s) and, more broadly, on exploring ways to treat cirrhosis. As Naim points out in his opening comment, these two issues— cirrhosis as a challenge and FGF-21s as a possible solution path —intersect in clear and exciting ways. He notes that the FGF-21 efruxifermin has been reported to have significant improvement in patients with cirrhosis, while the FGF-21 pegozafermin has shared positive results in a small cohort of patients. He also notes that a third FGF-21, efimosfermin alfa, has results in advanced non-cirrhotic MASH that suggest potential for similar efficacy in patients with cirrhosis, but this must be studied and confirmed in clinical trials. He mentions that resmetirom may also be showing signs of efficacy in some patients with cirrhosis. The entire package, he says, is a "game changer."Jörn notes that we are having parallel advances in treatment for advanced, non-cirrhotic patients. Sven concurs and comments that we are seeing effects that are not strictly related to metabolic disease. There is exceptional power that we can demonstrate one-level regression in sicker patients. The three agree that, at the same time, we are seeing cirrhosis trials that will lead to outcomes data; outcomes trials in non-cirrhotic medications may not be far away.Roger asks whether we are making progress in treating patients living with decompensated cirrhosis. Sven discusses what we are learning about treating portal hypertension, which is an important benefit unrelated to fibrosis regression. Simply improving portal hypertension will have an impact on endpoints. Naim points out that some ongoing trials include patients with cirrhosis, including survodutide and belapectin. Louise notes it will require "great P.R." to reverse some of the current perceptions about cirrhosis, but that this is "great." Naim states that even today, we have "a lot to offer" patients with portal hypertension or other symptoms of decompensation. As he concludes, he notes that this is underappreciated today. 

Audio from the 2024 Charleston Conference Leadership Interview Series. Heather Staines, Senior Strategy Consultant, Delta Think interviews Kamran Naim, the Head of Open Science at CERN (Conseil Européen pour la Recherche Nucléaire). CERN was founded in 1954 as a project not only to advance our fundamental understanding of basic scientific questions about who we are and where we come from but also as an instrument to get European countries to work together on a common scientific mission. It is the world's largest particle physics laboratory and largest research organization. In this conversation, Kamran tells us about his work as Head of Open Science at CERN to make all CERN research freely and publicly accessible.  Kamran has helped build national digital library access systems in countries like Pakistan, Madagascar, and Iraq. He has supported the Iraqi Virtual Science Library to reconnect scholar's post-conflict, and has worked with USAID on extending similar models across North and East Africa. Kamran was recruited to CERN to manage SCOAP³, the world's largest collective OA initiative, serving over 3,000 institutions. He works closely with librarians across the globe through CERN's partnerships and programs, and praises librarians as essential allies in open science. Video of the Interview is available at: https://youtu.be/v4CurNcHq60 Social Media: LinkedIn: https://www.linkedin.com/in/heatherstaines/ https://www.linkedin.com/in/kamran-naim-phd-20605012/ Keywords:    #CERN #OpenScience #OpenResearch #OpenAccess #OA #Research #ResearchAccess #GlobalResearch #DigitalInclusion #KnowledgeEquity #FutureOfResearch #LibraryInnovation #ScienceDiplomacy #DigitalLibraries #InformationAccess #Collaboration #ScientificCollaboration #ScholarlyCommunication #libraries #librarians #learning #learnon #information #leaders #leadership #AcademicLeadership #2024ChsConf #LibraryConference #podcast  #LeadershipInterview

00:00:00 - Surf's Up: Season 6 Episode 5Host Roger Green briefly describes this episode's three sections and introduces Roundtable guests. The Roundtable panel shares groundbreakers. 00:10:39 - Roundtable: A Deep Dive Into Drug Development, Part OneThe opening portion of this month's roundtable centers around two issues: exciting data for FGF-21s and, more generally, treating patients with cirrhosis. Naim Alkhouri sets the tone in his opening comments, which start by focusing on the exciting SYMMETRY data from efruxifermin and then hones in on FGF-21s and resmetirom in cirrhosis. The rest of the conversation features Jörh Schattenberg, Sven Francque and Naim discussing therapies in development for compensated and decompensating cirrhosis.00;24:44 - Newsmaker: Naga Chalasani on Real-World Experience Prescribing ResmetiromNaga joins Roger to discuss the paper Early Experience with resmetirom to treat Metabolic Dysfunction-Associated Steatohepatitis With Fibrosis in a Real-World Setting from his group at Indiana University, which his group authored and Hepatology Communications recently posted. The paper, based on IU Health's experience with its first 113 resmetirom patients, shares the group's practical experience developing processes to work closely with the specialty pharmacies dispensing resmetirom and, finally, concludes that a more engaged patient management strategy might reduce drug discontinuation to a level comparable with clinical trials.  00:47:21 - Expert: Scott Friedman on Gene Therapy, Diversity of Stellate Cell Types, Other Basic Liver ScienceScott and Roger cover a range of basis science topics in a fast-moving 19-minute discussion. It starts with Scott discussing the increasing acceptance that gene therapy is an acceptable way to treat a range of liver diseases, many of which are orphan or ultra-orphan but, in fact, include potential gene therapies for non-cirrhotic MASH and MASH cirrhosis. He notes that in addition to classic gene therapy, which introduces protective gene variants into the systems of patients with the risky variants, gene therapy is now looking to introduce FGF-21 into patients through genetic modification. From there, the conversation covers CAR-T therapy, the increasing ability to identify many different types of stellate cells and the idea that the most effective therapy for eary fibrosis, advanced fibrosis and cirrhosis might require fundamentally different kinds of interventions. The two final elements are the idea that what we now call "MASH" may be several diseases with different etiologies with similar manifestations and a passionate call for all of us to support maintaining NIH funding in whatever ways we can.01:06:45 - Business ReportAs Roger copes with his laryngitis, AI voices deliver an abbreviated business report 

Live from Building Blocks at Jaffa Port, Yitzy Hammer chats with Asaf Naim, co-founder of Kirobo, a trailblazer in Web3 since 2018. Asaf shares his journey from a taxation accountant to a self-taught programmer, sparked by a failed Bitcoin buy in 2011 and a client's lost crypto key in 2018. Kirobo pioneered account abstraction with "smart transactions," introducing the first undo button for crypto transfers. Now, they've launched Intentable (intentable.io) - the "Wix" of blockchain applications, a developer tool for rapid smart transaction creation, and are gearing up for Dappable (dappable.ai), an AI-driven platform to build DApps, tokens, and UIs in minutes. Asaf envisions Dappable as the next big Web3 driver, blending NFT and token innovation. Follow @Kirobo on Twitter for updates and join the revolution!Asaf on LinkedIn: https://www.linkedin.com/in/asafnaim/Check out Intentable: https://app.intentable.io/trading/top_pairs?utm_source=linkedin&utm_campaign=Profile

De la mano de 51 testimonios y diversos análisis, el documental "Texcoco, la decisión del presiente" nos habla de las implicaciones políticas y económicas; técnicas y sociales del Nuevo Aeropuerto Internacional de la Ciudad de México (NAIM); desde la planeación hasta la decisión de cancelar su construcción. Enrique Cárdenas, economista, nos habla al respecto. Para ver el documental y acceder a los libros: https://documentales.ceey.org.mx/ En otros temas: Claudia Sheinbaum se reunió con empresarios para hablar sobre los aranceles de Trump y presentó la estrategia que seguirá su gobierno como parte del Plan México / A diferencia de lo que sucedió con México, otros países reaccionan con más preocupación a los aranceles de Trump y anuncian medidas para contrarrestar los efectos de estas tarifas.

durée : 00:59:25 - Bouger les lignes - par : Nathalie Piolé -

Want to reach out to us? Want to leave a comment or review? Want to give us a suggestion or berate Anthony? Send us a text by clicking this link!Have you ever witnessed someone's profound spiritual awakening after years away from faith? Today we explore the miraculous spiritual resurrection that occurs when a soul returns to God through the sacrament of penance.Drawing from the Gospel of St. Luke, we contemplate Jesus raising the widow's son at Naim – a powerful metaphor for the Church weeping over souls lost to sin. St. Ambrose beautifully interprets this passage, showing how the grieving mother represents the Church herself, who never stops praying for those walking toward spiritual death. When Jesus commands "arise," we witness more than a physical resurrection; we see the pattern for spiritual revival that continues today.The testimony shared about a mother returning to confession after possibly 40 years demonstrates how our persistent prayers truly work. St. Padre Pio reassures us that "God is so good that not only does he never reject souls that convert, but he himself goes out in quest of the obstinate." This Lenten season, consider directing your sacrifices toward someone specific in your life who needs spiritual resurrection. The small annoyances we face daily, when offered up without complaint, become powerful prayers for conversion.I find particular inspiration in the connection between St. Ambrose and Augustine mentioned in today's reflection. Augustine's own journey from notorious sinner to saint, fueled by his mother Monica's relentless prayers, reminds us that no one is beyond the reach of God's mercy. Heaven truly rejoices when even one sinner returns. Whose spiritual resurrection will your prayers and sacrifices help bring about this Lent?Support the showSponsored by Recusant Cellars, an unapologetically Catholic and pro-life winery from Washington state. Use code BASED25 at checkout for 10% off! https://recusantcellars.com/Also sponsored by Quest Pipe Co. Get your St Isaac Jogues pipe here: https://questpipeco.com/discount/Amish?redirect=%2Fproducts%2Fst-isaac-jogues-limited-edition********************************************************Please subscribe! https://www.youtube.com/channel/UCKsxnv80ByFV4OGvt_kImjQ?sub_confirmation=1https://www.avoidingbabylon.comMerchandise: https://shop.avoidingbabylon.comLocals Community: https://avoidingbabylon.locals.comRSS Feed for Podcast Apps: https://feeds.buzzsprout.com/1987412.rssSpiritusTV: https://spiritustv.com/@avoidingbabylonRumble: https://rumble.com/c/AvoidingBabylon

11 And it came to pass afterwards, that he went into a city that is called Naim; and there went with him his disciples, and a great multitude.Et factum est : deinceps ibat in civitatem quae vocatur Naim : et ibant cum eo discipuli ejus et turba copiosa. 12 And when he came nigh to the gate of the city, behold a dead man was carried out, the only son of his mother; and she was a widow: and a great multitude of the city was with her.Cum autem appropinquaret portae civitatis, ecce defunctus efferebatur filius unicus matris suae : et haec vidua erat : et turba civitatis multa cum illa. 13 Whom when the Lord had seen, being moved with mercy towards her, he said to her: Weep not.Quam cum vidisset Dominus, misericordia motus super eam, dixit illi : Noli flere. 14 And he came near and touched the bier. And they that carried it, stood still. And he said: Young man, I say to thee, arise.Et accessit, et tetigit loculum. ( Hi autem qui portabant, steterunt.) Et ait : Adolescens, tibi dico, surge. 15 And he that was dead, sat up, and began to speak. And he gave him to his mother.Et resedit qui erat mortuus, et coepit loqui. Et dedit illum matri suae. 16 And there came a fear on them all: and they glorified God, saying: A great prophet is risen up among us: and, God hath visited his people.Accepit autem omnes timor : et magnificabant Deum, dicentes : Quia propheta magnus surrexit in nobis : et quia Deus visitavit plebem suam.

Have you ever asked God for a miracle? I have.Why not? We know and believe that God is all-powerful.When you are all-powerful, that means that it takes you no effort to do anything that you do.How difficult was it for God to create the universe? It was not difficult at all. It took no effort. How difficult to create my soul? Easy.How difficult is it for Him to work a miracle? He can work any miracle that He wants, at any time, no problem. Curing cancer, removing tumors, raising from the dead, curing blindness, whatever.Besides this, it seems that Our Lord wants us to ask for miracles.His word about having faith the grain of a mustard seed. “the apostles said to the Lord: Increase our faith. And the Lord said: If you had faith like to a grain of mustard seed, you might say to this mulberry tree, Be thou rooted up, and be thou transplanted into the sea: and it would obey you” (Lk. 17:5-6). This seems to be a gratuitous miracle, without any purpose, and Our Lord is saying that they could ask for that.Our Lord working so many miracles without being asked. Today's miracle of the multiplication of the loaves and fishes happened, even though there was no request or faith.Two Masses of this week will give us Our Lord's two greatest miracles: the raising from the dead of the son of the widow of Naim and the raising of Lazarus; in neither case was Our Lord asked to raise them from the dead.Meanwhile, there are many occasions in the Gospel when Our Lord immediately grants a request for Him to work a miracle. Most often, after He works the miracle, He praises the person for asking for the miracle and tells them it was because of their faith that He granted it. It seems that the manifestation of our faith by asking a miracle delights Him.Besides this, Our Lord encourages us to pray for whatever we need. His words are so strong and encouraging! “Ask, and it shall be given you: seek, and you shall find: knock, and it shall be opened to you. For every one that asketh, receiveth; and he that seeketh, findeth; and to him that knocketh, it shall be opened.” (Lk. 11:9-10)

00:00:00 - Surf's Up! Season 6 Episode 1SurfingMASH kicks off our sixth season in our new format, with three major elements to each episode. This week's Roundtable and Newsmakers segments focused on two recent conferences that took a multispecialty perspective on the range of medical and psychological issues affecting steatotic liver disease (a new concept specialty: steatology.") Our Expert this week is our co-host Jörn Schattenberg, discussing the educational and conceptual challenges of readying Europe for the EMA approval of resmetirom later this year.00:03:58 - Introductions and GroundbreakersHost Roger Green describes the new v2.0 format. He introduces the guests for this month's Roundtable discussion of the AASLD Emerging Trends conference: co-host Louise Campbell, hepatology KOL and EASL Secretary-General Aleksander Krag, Alcohol Use Disorder and Alcohol Liver Disease patient advocate and Sober Livers patient support organization co-founder Jenn Leigh Jones, and clinical hepatology Alexander Lalos. 00:15:46 - Roundtable: Highlights from the AASLD Emerging Trends Conference, Part 1The first portion of our Roundtable focuses on the emerging recognition throughout hepatology that MASLD, MetALD and ALD are best described as a disease spectrum, rather than discreet diseases. This has implications for the medical specialties involved in treatment and the entire way we look at this diseases.00:32:35 - Newsmakers: Arizona Liver Health Institute Chief Medical Officer Naim Alkhouri and Fatty Liver Alliance Founder Mike Betel Discuss the 2025 Deser Liver ConferenceNow in its fourth year, the Arizona Liver Health Institute's Desert Liver Conference has become a major multispecialty event on the Winter conference agenda. Arizona Liver Health Chief Medical Officer and hepatology KOL Naim Akhouri and patient advocate and Fatty Liver Alliance Founder Mike Betel join Roger Green to discuss the conference, including what makes it unique. Listen to Naim introduce a new description of the science of SLD.00:55:21 - Experts: SurfingMASH co-host and hepatology KOL Jörn Schattenberg joins Roger Green to discuss how Europe is preparing for the launch of resmetirom and his own focus on this issueOur third co-host, Jörn Schattenberg, could not join the February roundtable discussion. Here, he joins Roger to update listeners on his activities over the past six months. Most of the discussion centers around the necessary steps for Europe to prepare for the launch of resmetirom (anticipated to occur later this year), particularly given that the overall environment is more "siloed."01:11;15 - Wrap-up: Roger presents "the shortest Business Report ever"Roger discusses one continuing feature of Business Reports in the future from today and leaves all his other topics for next week.

America's Sweetheart Nems stops by to speak with Angela. Comedian Naim Lynn guest-hosts. A new Tell Us A Secret.See omnystudio.com/listener for privacy information.

America's Sweetheart Nems stops by to speak with Angela. Comedian Naim Lynn guest-hosts. A new Tell Us A Secret.See omnystudio.com/listener for privacy information.

Text us your thoughts on the episode or the show!The landscape of video production has undergone a seismic shift over the past decade. What was once a straightforward process of creating a single, polished piece of content has evolved into a complex ecosystem where every production must function across multiple platforms while maintaining its emotional impact.In our conversation with Christian Schu and David Siciliano, two veteran video producers working with major brands across continents, we explore how the fundamentals of video marketing have transformed. Christian, who creates content for high-end audio brands like Focal, Naim, and Bang & Olufsen, and David, who manages production for everything from performance marketing to major brand campaigns, share their perspectives on what makes modern video content effective.The most surprising revelation? Today's successful video producers think of themselves primarily as marketers rather than filmmakers. Both guests describe at length how understanding marketing strategy, target audiences, and desired outcomes has become essential to their work. As David puts it, "Your marketing budget is your video budget" – highlighting how completely these disciplines have merged. Christian adds that while technical aspects matter, ultimately "the product doesn't matter – it must be good, but anything besides that is only emotion."Whether you're a marketing professional collaborating with video teams or simply curious about how modern video content comes together, this episode offers valuable insights into the evolving relationship between storytelling, marketing strategy, and technical production. Listen now to discover why emotion trumps features and how your marketing content can benefit from a filmmaker's perspective.Episode Brought to You By MO Pros The #1 Community for Marketing Operations Professionals Connect Scattered Data with AI AgentsExplore how easy AI can be with Forwrd.ai for Marketing OpsBuild AI agents that can predict, forecast, segment, and automate the entire data processing workflow -- integrating, prepping, cleaning, normalizing, analyzing, and even building and operating your models. With Forward, you can get it done 100 times faster. Support the show

Dr. Naim Batik's journey through medicine is nothing short of extraordinary—12 years of Internal Medicine training across three countries, multiple visa rejections, and an unrelenting drive to become the best physician he can be. From 8 years of combined residency in Syria and Qatar to finally landing at Cook County Hospital in Chicago for his third IM residency, Naim's path is a masterclass in perseverance, adaptability, and clinical excellence. In this episode, we dive into his unique training experiences, his approach to clinical reasoning, and the lessons he's learned along the way. Whether you're a medical student, resident, or seasoned physician, you'll walk away inspired—and maybe a little in awe of his relentless dedication.Host: Andrew MohamaGuest: Naim BattikhProduced By: Andrew MohamaAlert & Oriented is a medical student-run clinical reasoning podcast dedicated to providing a unique platform for early learners to practice their skills as a team in real time. Through our podcast, we strive to foster a learning environment where medical students can engage with one another, share knowledge, and gain valuable experience in clinical reasoning. We aim to provide a comprehensive and supportive platform for early learners to develop their clinical reasoning skills, build confidence in their craft, and become the best clinicians they can be.Follow the team on X:A&OAndrew MohamaRich AbramsNU Internal MedA fantastic resource, by learners, for learners in Internal Medicine, Family Medicine, Pediatrics, Primary Care, Emergency Medicine, and Hospital Medicine.

Father Edward Looney reads and comments on The Life of Jesus Christ and Biblical Revelations: From the Visions of Anne Catherine Emmerich.Day 220Volume 3FROM THE SECOND PASCH TO THE RETURN FROM CYPRUSChapter 23: Jesus Goes from Misael, the Levitical City, through Thanach, Naim, Azanoth, and Damna to CapharnaumLEARN MORE - USE COUPON CODE ACE25 FOR 25% OFFThe Life of Jesus Christ and Biblical Revelations: From the Visions of Blessed Anne Catherine Emmerich Four-Book Set - https://bit.ly/3QVreIsThe Dolorous Passion of Our Lord Jesus Christ: From the Visions of Anne Catherine Emmerich - https://bit.ly/4bPsxRmThe Life and Revelations of Anne Catherine Emmerich Two-Book Set - https://bit.ly/3yxaLE5The Life of the Blessed Virgin Mary: From the Visions of Anne Catherine Emmerich - https://bit.ly/3wTRsULMary Magdalen in the Visions of Anne Catherine Emmerich - https://bit.ly/4brYEXbThe Mystical City of God Four-Book Set - https://bit.ly/44Q9nZbOur Lady of Good Help: Prayer Book for Pilgrims - https://bit.ly/3Ke6O9SThe Life of Jesus Christ in a Year: From the Visions of Anne Catherine Emmerich is a podcast from TAN that takes you through one of the most extraordinary books ever published. Follow along daily as Father Edward Looney works his way through the classic four-volume set, The Life of Jesus Christ and Biblical Revelations, by reading a passage from the book and then giving his commentary. Discover the visions of the famous 19th-century Catholic mystic, Blessed Anne Catherine Emmerich, a nun who was privileged by God to behold innumerable events of biblical times.Anne Catherine's visions included the birth, life, public ministry, Crucifixion, and Resurrection of Jesus Christ, as well as the founding of His Church. Besides describing persons, places, events, and traditions in intimate detail, she also sets forth the mystical significance of these visible realities. Here is the infinite love of God incarnate and made manifest for all to see, made all the more striking and vivid by the accounts Blessed Anne has relayed.Listen and subscribe to The Life of Jesus Christ in a Year: From the Visions of Anne Catherine Emmerich on your favorite podcast platform or at EmmerichPodcast.com.And for more great ways to deepen your faith, check out all the spiritual resources available at TANBooks.com and use Coupon Code ACE25 for 25% off your next order.

Father Edward Looney reads and comments on The Life of Jesus Christ and Biblical Revelations: From the Visions of Anne Catherine Emmerich.Day 219Volume 3FROM THE SECOND PASCH TO THE RETURN FROM CYPRUSChapter 23: Jesus Goes from Misael, the Levitical City, through Thanach, Naim, Azanoth, and Damna to CapharnaumLEARN MORE - USE COUPON CODE ACE25 FOR 25% OFFThe Life of Jesus Christ and Biblical Revelations: From the Visions of Blessed Anne Catherine Emmerich Four-Book Set - https://bit.ly/3QVreIsThe Dolorous Passion of Our Lord Jesus Christ: From the Visions of Anne Catherine Emmerich - https://bit.ly/4bPsxRmThe Life and Revelations of Anne Catherine Emmerich Two-Book Set - https://bit.ly/3yxaLE5The Life of the Blessed Virgin Mary: From the Visions of Anne Catherine Emmerich - https://bit.ly/3wTRsULMary Magdalen in the Visions of Anne Catherine Emmerich - https://bit.ly/4brYEXbThe Mystical City of God Four-Book Set - https://bit.ly/44Q9nZbOur Lady of Good Help: Prayer Book for Pilgrims - https://bit.ly/3Ke6O9SThe Life of Jesus Christ in a Year: From the Visions of Anne Catherine Emmerich is a podcast from TAN that takes you through one of the most extraordinary books ever published. Follow along daily as Father Edward Looney works his way through the classic four-volume set, The Life of Jesus Christ and Biblical Revelations, by reading a passage from the book and then giving his commentary. Discover the visions of the famous 19th-century Catholic mystic, Blessed Anne Catherine Emmerich, a nun who was privileged by God to behold innumerable events of biblical times.Anne Catherine's visions included the birth, life, public ministry, Crucifixion, and Resurrection of Jesus Christ, as well as the founding of His Church. Besides describing persons, places, events, and traditions in intimate detail, she also sets forth the mystical significance of these visible realities. Here is the infinite love of God incarnate and made manifest for all to see, made all the more striking and vivid by the accounts Blessed Anne has relayed.Listen and subscribe to The Life of Jesus Christ in a Year: From the Visions of Anne Catherine Emmerich on your favorite podcast platform or at EmmerichPodcast.com.And for more great ways to deepen your faith, check out all the spiritual resources available at TANBooks.com and use Coupon Code ACE25 for 25% off your next order.

Sarah Montague speaks to Basem Naim, a senior political figure in Hamas. Its violence and hostage-taking on October 7th led to an overwhelming Israeli onslaught in Gaza. A fragile ceasefire is now in place, but how can long-term peace be achieved?

What has Hamas achieved after 15 months of war with Israel?With the assassination of two of its most senior leaders, and the devastating human toll in Gaza, the future of Hamas appears uncertain.But the scenes of its militia re-emerging hours after the ceasefire sent a message of defiance.The scenes outraged an Israeli public, who were told that  victory would only come after the complete destruction of Hamas.While the world prays for an end to the violence in Gaza, Hamas' senior leaders say a new chapter of their fight against Israel is expected - this time in the West Bank.As settler-led violence and Israeli military raids on Palestinian villages reach historic levels, many have lost hope that the Palestinian Authority and its president Mahmoud Abbas can do anything to protect Palestinians from another all-out war.Instead, the lure of armed resistance championed by Hamas has influenced a generation of disillusioned and angry young Palestinians, who've given up hope that diplomacy offers them any future.This week on The Big Picture Podcast, we speak with senior Hamas official Basem Naim, who is a former health minister in Gaza and now part of the group's political bureau. Naim believes that Gaza was only the first chapter in the war, and that the next will be more complicated and ultimately more devastating.We'd love to hear your thoughts on this episode, and any guests you'd like us to have on our show. Reach us by email at mh@middleeasteye.org or find us on instagram @BigPictureMee.You can also watch all our episodes on our YouTube channel here: https://www.youtube.com/playlist?list=PLMyaP73Ho1ySj3cO0OSOHZAOgD1WTDixG

In this episode, Naim Alkhouri, Mike Betel, Michelle Long and Jeff McIntyre join Jörn Schattenberg and Roger Green to look back at The Liver Meeting 2024. This conversation considers how the anticipated approval of a second MASH drug without biopsy might affect clinical trials and discusses two recent publications on patient genotyping and patient clusters. The conversation starts with Roger asking the group whether the presence of two approved MASH medications that do not require biopsy will make recruiting clinical trials that require them more challenging. The group doubts this will not add a significant new challenge to already-challenging trial recruitment. Naim comments that while this is a concern, it is already factored into trial schedules and that, given the number of patients available for trial, this should be highly manageable. Michelle discusses the importance of risk stratification in overall trial enrollment and this issue. Jeff and Mike agree that while this is a concern, it is part of a broader concern about the use of biopsy and should not in itself be a primary focus in terms of trial design at this point in time. Naim introduces two other topics he considers worthy of consideration: the impact of synergy between resmetirom and GLP-1 agonists and the importance of different genetic polymorphisms in predicting the impact of drugs on specific patients. On synergy, he comments that MAESTRO-NASH data suggests that the presence of a GLP-1 does not affect the impact of resmetirom on fibrosis level. On the second point, he notes that several papers looked at major genotypes like PNPLA3 and HD17N13 and specifically cites a late-breaker from Arun Sanyal indicating that g-allele status may impact MASH independent of weight or insulin. Michelle mentions a recent paper in Nature identifying distinct clusters of patients based on how their SLDs progress over time, with a two-cluster solution indicating patients with concomitant diabetes and obesity vs. those without these two concomitant diseases. Roger shares a key point from each paper on treatment in the US. Data in the PNPLA3 paper might suggest that the course of disease in Hispanics, who have high levels of g-allele abnormalities, might be different from other ethnic groups with far lower abnormality rates. He also notes that the faster disease progression in the non-metabolic cluster highlights the importance of learning more about Lean MASH and how to treat it, since faster progression of disease suggests later diagnosis and higher morbidity, mortality and treatment costs levels.

In this episode, Naim Alkhouri, Mike Betel, Michelle Long and Jeff McIntyre join Jörn Schattenberg and Roger Green to look back at The Liver Meeting 2024. This conversation reviews the ESSENCE trial, the Phase 3 trial demonstrating that semaglutide regresses fibrosis levels in some MASH patients.  The conversation begins with each panelist sharing a word or short phrase they felt best captured their feelings about TLM2024. Next, panelists review the meeting's most consequential paper, the ESSENCE Trial. Naim starts by describing ESSENCE, a Phase 3 trial with semaglutide demonstrating significant levels of fibrosis regression in non-cirrhotic MASH patients. Jörn adds the hopeful note that NITs performed as well as or better than biopsy in this trial, which he hopes will speed the transition in diagnostic approaches and tools. Jeff and Mike agree that from the patient's perspective, ESSENCE will be seen as a milestone in MASH therapy: the proof that a second drug can succeed in MASH. As the conversation ends, Roger notes that approval of a second agent for a particular disease often leads to dramatic growth in overall drug treatment by changing the pivotal question from whether to treat with a drug to which choice to prescribe. 

In this episode of the Property Profits Real Estate Podcast, host Dave Dubeau chats with real estate entrepreneur Ken Naim, who shares his innovative approach to investing in suburban office spaces. As an asset class often overlooked, suburban offices offer incredible value-add opportunities, especially in a post-pandemic market. Key Takeaways: Why Suburban Offices? Ken explains why suburban office spaces are outperforming their downtown counterparts, with higher occupancy rates and greater appeal for both employers and employees seeking work-life balance. Value-Add Strategies: Offering unique amenities like shared training rooms, outdoor picnic spaces, and upgraded interiors. Targeting properties with 60-80% occupancy to optimize returns through lease-ups or rent increases. Transforming underutilized areas (e.g., storage rooms or parking lots) into income-generating spaces. Case Studies from Ken's Portfolio: Recent acquisitions include a 92,000-square-foot office building in Cincinnati, a 57,000-square-foot property in Dayton, and a 37,000-square-foot office in Orlando. Diversification into retail, industrial, and land entitlement projects. Challenges in Office Space Investing: Longer leasing cycles compared to residential properties. Handling tenant improvement (TI) requests while balancing costs. The importance of creative problem-solving to differentiate properties in a competitive market. Future Goals: Ken plans to close 5-6 new commercial projects over the next 18 months, focusing on properties with high cash-on-cash return potential and opportunities to double NOI through strategic improvements. Ken's Investment Model: While he initially self-financed, Ken now collaborates with partners and investors, ensuring projects are both profitable and low-risk for everyone involved. - Get Interviewed on the Show! - ================================== Are you a real estate investor with some 'tales from the trenches' you'd like to share with our audience? Want to get great exposure and be seen as a bonafide real estate pro by your friends? Would you like to inspire other people to take action with real estate investing? Then we'd love to interview you! Find out more and pick the date here: http://daveinterviewsyou.com/  

Your daily news in under three minutes. At Al Jazeera Podcasts, we want to hear from you, our listeners. So, please head to https://www.aljazeera.com/survey and tell us your thoughts about this show and other Al Jazeera podcasts. It only takes a few minutes! Connect with us: @AJEPodcasts on Twitter, Instagram, Facebook

Koki Nakano is a composer and a pianist, born in 1988 in Fukuoka, Japan. After graduating Music High School at Toho Gakuen School of Music in Tokyo, he enrolled at the composition department of Tokyo University of the Arts. He has performed recitals at the Louvre and the Théâtre du Châtelet (Paris), Cadogan Hall (London), Lincoln Center (New York). He released his first album Lift in 2016, in collaboration with French cellist Vincent Segal under the Paris-based label Nø Førmat!. ​In 2019, Koki took part in a research workshop at the Reborn Art Festival in the landscapes of Ishinomaki‘s bay. Accompanied by renowned visual artist Kohei Nawa, famous choreographer Damien Jalet, and few dancers, they explore different points of fusion between the human body and the landscape. ​His second album Pre-choreographed is released in April 2020. Koki mixed his classical pieces with electronic sounds and he developed this relationship between dance and music. In 2021, Koki composed the original music for Damien Jalet's piece ‘Brise-lames' and performed it live at Palais Garnier for Paris Opera's opening gala. His third album, Oceanic Feeling is released in 2022 as well as four musical videos gathering choreographers and dancers Tess Voelker and Nicolas Huchard, Marion Motin, Mourad Bouayad. ​Koki Nakano's new album Ululō is released in October 2024, in collaboration with singers Yaël Naim, Wayne Snow and Jordy.

Father Edward Looney reads and comments on The Life of Jesus Christ and Biblical Revelations: From the Visions of Anne Catherine Emmerich.Day 152Volume 3PREACHING AND MIRACLES OF JESUS IN CAPHARNAUM AND THE SURROUNDING DISTRICTSChapter 3: The Raising of the Youth of Naim From the DeadLEARN MORE - USE COUPON CODE ACE25 FOR 25% OFFThe Life of Jesus Christ and Biblical Revelations: From the Visions of Blessed Anne Catherine Emmerich Four-Book Set - https://bit.ly/3QVreIsThe Dolorous Passion of Our Lord Jesus Christ: From the Visions of Anne Catherine Emmerich - https://bit.ly/4bPsxRmThe Life and Revelations of Anne Catherine Emmerich Two-Book Set - https://bit.ly/3yxaLE5The Life of the Blessed Virgin Mary: From the Visions of Anne Catherine Emmerich - https://bit.ly/3wTRsULMary Magdalen in the Visions of Anne Catherine Emmerich - https://bit.ly/4brYEXbThe Mystical City of God Four-Book Set - https://bit.ly/44Q9nZbOur Lady of Good Help: Prayer Book for Pilgrims - https://bit.ly/3Ke6O9SThe Life of Jesus Christ in a Year: From the Visions of Anne Catherine Emmerich is a podcast from TAN that takes you through one of the most extraordinary books ever published. Follow along daily as Father Edward Looney works his way through the classic four-volume set, The Life of Jesus Christ and Biblical Revelations, by reading a passage from the book and then giving his commentary. Discover the visions of the famous 19th-century Catholic mystic, Blessed Anne Catherine Emmerich, a nun who was privileged by God to behold innumerable events of biblical times.Anne Catherine's visions included the birth, life, public ministry, Crucifixion, and Resurrection of Jesus Christ, as well as the founding of His Church. Besides describing persons, places, events, and traditions in intimate detail, she also sets forth the mystical significance of these visible realities. Here is the infinite love of God incarnate and made manifest for all to see, made all the more striking and vivid by the accounts Blessed Anne has relayed.Listen and subscribe to The Life of Jesus Christ in a Year: From the Visions of Anne Catherine Emmerich on your favorite podcast platform or at EmmerichPodcast.com.And for more great ways to deepen your faith, check out all the spiritual resources available at TANBooks.com and use Coupon Code ACE25 for 25% off your next order.

Ash Patel and Amanda Cruz interview Ken Naim, a commercial real estate investor and manager at Beacon One Capital. Ken discusses the current state of the office market, dispelling myths about its toxicity and highlighting the opportunities available for savvy investors. He shares insights on buying and selling strategies, the importance of creating attractive office spaces, and the challenges of land entitlement projects. Ken also reflects on a significant lesson learned from a land development failure, emphasizing the need for thorough documentation and understanding of local government processes. The conversation concludes with Ken's preference for commercial buildings over land development due to their predictability and lower political risks. Sponsors: Altra Running Learn more about your ad choices. Visit megaphone.fm/adchoices

The Encounter series by D.M. Griffin looks at four women who each had a brief encounter with Jesus and its profound effect on their lives. The final book, Return of the Son just released. Listen in to see what you'll find in the covers of this Biblical fiction novel.  note: links may be affiliate links that provide me with a small commission at no extra expense to you.  Have you ever wondered who the "Widow of Naim" might have been?  Griffin takes a look at what could have led up to the heartbreaking moment that led to one of Jesus' encounters with broken people.    Don't miss her first episode HERE. Return of the Son by D. M. Griffin Her life was perfect. At least her childhood was. Eve never wanted anything except her father's presence. As a prominent advisor to the evil King Herod, Eve's father was split between his duties to the king and his duties as the only living parent for his daughter. With no heir to claim his family's land, Eve's father did what any loving father would do. He arranged for her betrothal. But this wasn't just any betrothal. Her potential husband was related to the king she despised. With a rough marital journey ahead of her, she tenuously clings to the promises of God. Not sharing her father's enthusiasm or respect for the Herodian dynasty, Eve acted like the spoiled child she was upon first meeting her betrothed. With faulty expectations and prejudiced opinions, she did what she could to ruin the marriage before it began. It wasn't until it was almost too late that Eve's eyes were open and she saw the opportunity to experience love for the divine intervention that it was. Fraught with political intrigue and personal challenges, would Eve be able to fully surrender to the life God wanted her to live by loving a man she thought she could never love? When that man's shadows chase the family into the future, would Eve's son pay the ultimate price? Or would God intervene there too? Could He? Only a single, unforeseen encounter could answer Eve's impossible question. Does love truly conquer death?  Learn more about Demi on her  WEBSITE and follow her on GoodReads and BookBub. Like to listen on the go? You can find Because Fiction Podcast at: Apple  Castbox  Google Play Libsyn  RSS Spotify Amazon and more!

"PREVIEW: HEZBOLLAH: Colleague David Doud comments on Tehran's choice to lead its surrogate gunmen, Hezbollah -- a senior and uninspiring propagandist Naim Qassem, who the IDF regards as a target. More later." 1914 Beirut

Monocle's Christopher Cermak reports from Washington as Emma Nelson discusses Hezbollah's new leader choice with Edmund Bower in Beirut. Plus: influence operations and disinformation in Switzerland, historic Italian naval ship docks in Singapore and Bangkok's Jay Fai announces that she is hanging up her apron. See omnystudio.com/listener for privacy information.

In our news wrap Tuesday, Hezbollah has chosen cleric Naim Kassem as its new leader, Ukrainian President Zelenskyy warned that Russia's planned use of North Korean troops on the front lines would push the war "beyond the borders" of Ukraine and Russia and President Biden is awarding nearly $3 billion to reduce air pollution from the nation's ports. PBS News is supported by - https://www.pbs.org/newshour/about/funders

In our news wrap Tuesday, Hezbollah has chosen cleric Naim Kassem as its new leader, Ukrainian President Zelenskyy warned that Russia's planned use of North Korean troops on the front lines would push the war "beyond the borders" of Ukraine and Russia and President Biden is awarding nearly $3 billion to reduce air pollution from the nation's ports. PBS News is supported by - https://www.pbs.org/newshour/about/funders

Welcome to The Times of Israel's Daily Briefing, your 20-minute audio update on what's happening in Israel, the Middle East and the Jewish world. Military reporter Emanuel Fabian joins host Amanda Borschel-Dan on today's episode. Four IDF soldiers fell in the Gaza Strip yesterday: Cpt. Daniel Mimon Toaff, 23; Staff Sgt. Agam Naim, 20; Staff Sgt. Amit Bakri, 21; and Staff Sgt. Dotan Shimon, 21. We discuss how the death of Naim, a paramedic, marks the first female soldier to be killed in the ground offensive. A massive attack against Hezbollah operatives that is being attributed to Israel saw the explosion of thousands of pagers yesterday a few hours after Israel announced an additional official war goal: getting displaced residents of the north back to their homes. Fabian fills us in on what we're hearing from foreign reports and the possibility of retaliation. The Shin Bet foiled a recent attempt by Hezbollah to assassinate a former senior Israeli security official using a remotely detonated explosive device, the security agency announced on Tuesday. Fabian explains how Hezbollah likely has recruits in Israel to carry out such attacks. The Israeli military clarified on Sunday that there was no evacuation recommendation given for civilians in southern Lebanon, and that flyers dropped in the southern village of Wazzani calling on residents to leave had been distributed by a brigade commander without permission. How could this have happened? For news updates, please check out The Times of Israel's ongoing live blog. Discussed articles include: 4 IDF troops killed, several hurt during fighting in southern Gaza's Rafah 9 killed, almost 3,000 injured as vast wave of pager explosions strikes Hezbollah Analysts say Mossad likely hid explosives in pagers before they reached Hezbollah IDF urges vigilance as defense chiefs meet amid Hezbollah retaliation threat Shin Bet says it foiled Hezbollah attempt to kill former top Israeli security official After unauthorized flyers dropped, IDF says there's no south Lebanon evacuation order Subscribe to The Times of Israel Daily Briefing on Apple Podcasts, Spotify, YouTube, or wherever you get your podcasts. This episode was produced by the Pod Waves. IMAGE: Lebanese first responders carry a man who was wounded after his handheld pager exploded in an attack blamed on Israel targeting Hezbollah, in the southern port city of Sidon, Lebanon, September 17, 2024. (AP Photo)See omnystudio.com/listener for privacy information.